Management of refractory autoimmune hepatitis with rituximab: a case series.

ABSTRACT:

Background and aims

Most patients with autoimmune hepatitis respond to the standard of care of prednisolone in combination with a thiopurine, or a second line of mycophenolate mofetil or tacrolimus. This study aims to add to the reported experience of using rituximab in the small numbers of patients with autoimmune hepatitis who are refractory or intolerant to these treatments.

Case presentation

A retrospective single center case series was performed on six patients who were treated with rituximab for probable or definite, biopsy-proven type 1 autoimmune hepatitis over a 9-year period. They were Caucasian, three males and three females, with an age at autoimmune hepatitis diagnosis ranging from 16 to 52 years old. Three patients had cirrhosis. All six patients had trialed pr

SUBMITTER: Batt NM 

PROVIDER: S-EPMC12645696 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature